Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...

Interestingly, glipizide was very similar to repaglinide with respect to the effects on the early phase. Moreover, glipizide reached significance against glibenclamide in both groups of subjects ...

Potential side effects include increased heart rates, hepatic glucose production, and loss of lean mass. Researchers have proposed combining GCGR agonists with insulinotropic agents, such as GLP-1 ...